Free Trial
NASDAQ:HOOK

HOOKIPA Pharma Q2 2024 Earnings Report

HOOKIPA Pharma logo
$0.88 +0.04 (+4.78%)
As of 08/8/2025 03:47 PM Eastern

HOOKIPA Pharma EPS Results

Actual EPS
-$1.52
Consensus EPS
-$1.44
Beat/Miss
Missed by -$0.08
One Year Ago EPS
N/A

HOOKIPA Pharma Revenue Results

Actual Revenue
$1.29 million
Expected Revenue
$5.68 million
Beat/Miss
Missed by -$4.39 million
YoY Revenue Growth
N/A

HOOKIPA Pharma Announcement Details

Quarter
Q2 2024
Time
After Market Closes
Conference Call Date
Thursday, August 8, 2024
Conference Call Time
4:00PM ET

Upcoming Earnings

HOOKIPA Pharma's Q2 2025 earnings is scheduled for Thursday, August 14, 2025, with a conference call scheduled on Friday, August 15, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

HOOKIPA Pharma Earnings Headlines

HIDDEN IN THE BOOK OF GENESIS…
“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 trillion vault of untapped American wealth. Former CIA advisor Jim Rickards calls it the “Old Testament Wealth Code” — and says it could transform your financial future. He’s revealing everything in a new presentation.
Hookipa Pharma Inc News (HOOK) - Investing.com
See More HOOKIPA Pharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like HOOKIPA Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on HOOKIPA Pharma and other key companies, straight to your email.

About HOOKIPA Pharma

HOOKIPA Pharma (NASDAQ:HOOK), a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in preclinical studies for the treatment of human papillomavirus-positive cancers. The company has a collaboration with Gilead Sciences, Inc. to develop arenavirus based therapeutics to treat hepatitis B virus and human immunodeficiency virus infections. HOOKIPA Pharma Inc. was founded in 2011 and is headquartered in New York, New York.

View HOOKIPA Pharma Profile

More Earnings Resources from MarketBeat